Shares of Sanofi (NYSE:SNY) have received a consensus rating of “Hold” from the seventeen brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $55.00.

A number of brokerages have commented on SNY. Berenberg Bank cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a report on Friday. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a report on Friday, June 2nd. Argus increased their target price on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Finally, TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th.

Sanofi (NYSE:SNY) traded up 0.53% on Monday, hitting $49.59. 1,089,619 shares of the company traded hands. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24. The firm has a market capitalization of $125.24 billion, a PE ratio of 12.24 and a beta of 0.93. The firm’s 50 day moving average price is $48.82 and its 200 day moving average price is $44.16.

Sanofi (NYSE:SNY) last announced its earnings results on Friday, April 28th. The company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.03. Sanofi had a return on equity of 25.89% and a net margin of 26.55%. The business had revenue of $8.65 billion during the quarter, compared to analysts’ expectations of $8.40 billion. The company’s revenue was up 1.2% compared to the same quarter last year. Equities research analysts predict that Sanofi will post $3.15 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of SNY. Manning & Napier Advisors LLC boosted its stake in Sanofi by 8.0% in the first quarter. Manning & Napier Advisors LLC now owns 244,282 shares of the company’s stock valued at $11,052,000 after buying an additional 18,094 shares in the last quarter. Foundry Partners LLC boosted its stake in Sanofi by 26.7% in the first quarter. Foundry Partners LLC now owns 225,375 shares of the company’s stock valued at $10,198,000 after buying an additional 47,485 shares in the last quarter. Beacon Financial Group boosted its stake in Sanofi by 0.9% in the first quarter. Beacon Financial Group now owns 79,526 shares of the company’s stock valued at $3,566,000 after buying an additional 725 shares in the last quarter. Philadelphia Trust Co. boosted its stake in Sanofi by 7.6% in the fourth quarter. Philadelphia Trust Co. now owns 49,300 shares of the company’s stock valued at $1,994,000 after buying an additional 3,500 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in Sanofi during the fourth quarter valued at approximately $483,000. 9.84% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Sanofi (SNY) Given Consensus Recommendation of “Hold” by Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/06/26/sanofi-sny-given-consensus-recommendation-of-hold-by-brokerages.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.